Parenteral Drugs (India) Limited
NSE: PDPL
NSE
2.90
0.00 (0.00%)
Prev Close
2.9
Open Price
2.7
Volume
1,063
Today Low / High
2.7 / 2.9
52 WK Low / High
2.7 / 2.9
Range
3 - 3
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 2.9, with a change of 0 (0%). The expected target range on the NSE is between 3 - 3. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Parenteral Drugs (India) Limited Graph
Parenteral Drugs (India) Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Parenteral Drugs (India) Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2.90 | 2.93 | 2.64 - 3.22 |
| 2.96 | 2.37 - 3.55 | ||
| 2.99 | 2.09 - 3.88 | ||
| Bearish Scenario | 2.90 | 2.87 | 2.58 - 3.16 |
| 2.84 | 2.27 - 3.41 | ||
| 2.81 | 1.97 - 3.66 |
Overview of Parenteral Drugs (India) Limited
ISIN
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
0
Market Cap
101,077,183
Last Dividend
0
Official Website
IPO Date
2010-08-19
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of PDPL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2010-09-13 | September 13, 10 | 1.12503 | 1.12503 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | 8.50 Cr | 5.47 Cr | 3.03 Cr | 0.3567 | 0.00 Cr | 0.00 Cr | -0.01 Cr | -76.36 Cr | -25.61 | 37.27 Cr | -8.9877 |
| 2021-03-31 | 12.15 Cr | 7.32 Cr | 4.84 Cr | 0.3980 | 0.00 Cr | 0.94 Cr | -0.01 Cr | -121.71 Cr | -40.82 | -11.71 Cr | -10.0155 |
| 2020-03-31 | 24.03 Cr | 22.69 Cr | 1.34 Cr | 0.0558 | 0.00 Cr | 1.03 Cr | -0.03 Cr | -114.07 Cr | -38.26 | -14.44 Cr | -4.7481 |
| 2019-03-31 | 32.00 Cr | 24.43 Cr | 7.56 Cr | 0.2364 | 0.00 Cr | 1.54 Cr | -0.09 Cr | -147.91 Cr | -49.61 | -16.24 Cr | -4.6223 |
| 2018-03-31 | 216.81 Cr | 179.71 Cr | 37.09 Cr | 0.1711 | 0.00 Cr | 3.68 Cr | -42.51 Cr | -118.94 Cr | -39.89 | -1.29 Cr | -0.5486 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | 0.00 Cr | 484.23 Cr | 1,308.14 Cr | -824.0306 Cr | 107.20 Cr | 107.20 Cr | 1.03 Cr | 205.44 Cr | 0.00 Cr | 0.00 Cr | 2.40 Cr | 1,200.8375 Cr |
| 2021-03-31 | 0.06 Cr | 568.20 Cr | 1,250.96 Cr | -682.8770 Cr | 1,071.62 Cr | 1,071.56 Cr | 1.59 Cr | 321.81 Cr | 84.95 Cr | 0.12 Cr | 0.00 Cr | 1,143.6389 Cr |
| 2020-03-31 | 0.11 Cr | 551.85 Cr | 1,113.03 Cr | -561.3060 Cr | 946.19 Cr | 946.08 Cr | 1.26 Cr | 339.14 Cr | 72.15 Cr | 0.14 Cr | 0.00 Cr | 1,005.7016 Cr |
| 2019-03-31 | 0.10 Cr | 540.57 Cr | 987.37 Cr | -446.9213 Cr | 839.91 Cr | 839.82 Cr | 3.97 Cr | 356.49 Cr | 51.99 Cr | 0.15 Cr | 0.00 Cr | 877.5472 Cr |
| 2018-03-31 | 0.08 Cr | 890.42 Cr | 1,026.58 Cr | -136.4374 Cr | 824.55 Cr | 824.48 Cr | 27.01 Cr | 715.80 Cr | 16.88 Cr | 0.17 Cr | 0.00 Cr | 592.5632 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | -0.4827 Cr | 64.7252 Cr | -64.2994 Cr | -0.4827 Cr | -0.0569 Cr | 0.0001 Cr | 0.0000 Cr | -109.1261 Cr | 35.1376 Cr | 0.0000 Cr | 0.5636 Cr |
| 2021-03-31 | 125.3221 Cr | 0.0619 Cr | -125.4351 Cr | 125.3221 Cr | -0.0511 Cr | 0.0570 Cr | 0.0000 Cr | -154.4719 Cr | 125.4342 Cr | 0.0000 Cr | -0.3356 Cr |
| 2020-03-31 | 112.3633 Cr | 0.0789 Cr | -112.4294 Cr | 112.3633 Cr | 0.0128 Cr | 0.1081 Cr | 0.0000 Cr | -141.7361 Cr | -2.4732 Cr | 0.0000 Cr | 2.7152 Cr |
| 2019-03-31 | 477.0348 Cr | 96.5765 Cr | -573.5925 Cr | 477.0348 Cr | 0.0189 Cr | 0.0953 Cr | 0.0000 Cr | -181.3979 Cr | -324.1768 Cr | 0.0000 Cr | 23.0437 Cr |
| 2018-03-31 | 166.9528 Cr | -0.6184 Cr | -166.6188 Cr | 165.5609 Cr | -0.2845 Cr | 0.0764 Cr | -1.3919 Cr | -141.2500 Cr | -69.3203 Cr | 0.0000 Cr | 18.0384 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | 1.77 Cr | 1.76 Cr | 0.02 Cr | 0.0088 | 19.21 Cr | 23.81 Cr | 7.99 | 46.37 Cr | 13.4301 |
| 2021-12-31 | 1.44 Cr | 0.60 Cr | 0.84 Cr | 0.5858 | -7.55 Cr | -34.52 Cr | -11.58 | -3.21 Cr | -23.9374 |
| 2021-09-30 | 2.35 Cr | 1.47 Cr | 0.88 Cr | 0.3758 | -7.60 Cr | -33.61 Cr | -11.27 | -3.26 Cr | -14.3017 |
| 2021-06-30 | 2.93 Cr | 1.64 Cr | 1.29 Cr | 0.4392 | -6.97 Cr | -32.04 Cr | -10.74 | -2.62 Cr | -10.9318 |
| 2021-03-31 | 2.55 Cr | 2.92 Cr | -0.36 Cr | -0.1426 | -0.88 Cr | -24.85 Cr | -8.33 | 3.41 Cr | -9.7246 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 1.03 Cr | 67.14 Cr | 205.44 Cr | 484.23 Cr | 1,308.14 Cr |
| 2021-12-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2021-09-30 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.64 Cr | 67.33 Cr | 313.15 Cr | 577.32 Cr | 1,325.70 Cr |
| 2021-06-30 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2021-03-31 | 0.06 Cr | 0.00 Cr | 0.06 Cr | 0.00 Cr | 1.59 Cr | 68.07 Cr | 321.81 Cr | 568.20 Cr | 1,250.96 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | 0.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2021-12-31 | -0.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2021-09-30 | -0.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2021-06-30 | -0.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2021-03-31 | -0.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2010-09-13 | September 13, 10 | 133333:100000 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,641.80 | ₹3,939,137,904,000.00 | ₹2,098,280.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,151.50 | ₹1,633,032,553,500.00 | ₹681,521.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,685.30 | ₹1,247,271,358,500.00 | ₹279,863.00 |
| Mankind Pharma Limited | MANKIND | ₹2,606.80 | ₹1,075,901,331,568.00 | ₹731,305.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,277.60 | ₹1,063,387,459,020.00 | ₹1,229,762.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.80 | ₹994,960,224,000.00 | ₹307,413.00 |
| Lupin Limited | LUPIN | ₹1,974.70 | ₹901,938,300,900.00 | ₹380,522.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,426.00 | ₹648,759,690,000.00 | ₹99,581.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.40 | ₹610,074,420,800.00 | ₹1,872,840.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,937.30 | ₹546,707,997,300.00 | ₹466,930.00 |
| Laurus Labs Limited | LAURUSLABS | ₹879.10 | ₹474,560,157,500.00 | ₹1,548,001.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,418.40 | ₹359,853,753,600.00 | ₹437,395.00 |
| Cohance Lifesciences Limited | COHANCE | ₹884.70 | ₹338,457,031,978.00 | ₹105,334.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,638.50 | ₹329,643,636,000.00 | ₹49,045.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,747.90 | ₹273,268,433,900.00 | ₹250,994.00 |
| Piramal Enterprises Limited | PEL | ₹1,167.70 | ₹264,691,900,600.00 | ₹183,898.00 |
| Eris Lifesciences Limited | ERIS | ₹1,768.70 | ₹240,909,320,900.00 | ₹37,828.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,479.40 | ₹240,371,432,600.00 | ₹246,819.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,433.00 | ₹210,825,000,000.00 | ₹11,150.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹974.60 | ₹191,570,299,800.00 | ₹29,498.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,888.00 | ₹178,181,651,200.00 | ₹28,474.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,083.00 | ₹172,501,323,000.00 | ₹140,398.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,168.10 | ₹164,800,966,770.00 | ₹172,510.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹882.45 | ₹158,055,619,500.00 | ₹259,072.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹458.50 | ₹111,252,274,000.00 | ₹945,550.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,581.50 | ₹109,248,951,100.00 | ₹46,177.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹851.90 | ₹83,308,067,710.00 | ₹36,218.00 |
| Strides Pharma Science Limited | STAR | ₹865.50 | ₹79,775,471,850.00 | ₹92,326.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹863.25 | ₹78,240,335,715.00 | ₹294,141.00 |
| FDC Limited | FDC | ₹474.65 | ₹77,277,766,500.00 | ₹198,253.00 |
| Innova Captab Limited | INNOVACAP | ₹911.35 | ₹52,151,939,956.00 | ₹70,484.00 |
| Suven Life Sciences Limited | SUVEN | ₹230.75 | ₹50,320,575,500.00 | ₹56,095.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹146.08 | ₹47,406,173,760.00 | ₹195,028.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹483.05 | ₹44,087,973,500.00 | ₹160,106.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.85 | ₹44,021,409,750.00 | ₹240,104.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹772.20 | ₹39,165,289,020.00 | ₹31,316.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,358.20 | ₹39,002,269,800.00 | ₹5,512.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹363.25 | ₹36,425,983,500.00 | ₹39,528.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹502.80 | ₹35,400,036,240.00 | ₹9,585.00 |
| Hikal Limited | HIKAL | ₹254.90 | ₹31,429,424,900.00 | ₹3,140,867.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹631.60 | ₹30,413,434,800.00 | ₹53,855.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹96.82 | ₹28,419,284,140.00 | ₹848,541.00 |
| Alembic Limited | ALEMBICLTD | ₹105.52 | ₹27,095,636,534.00 | ₹249,022.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.03 | ₹26,866,184,620.00 | ₹2,369,065.00 |
| Indoco Remedies Limited | INDOCO | ₹279.55 | ₹25,787,900,445.00 | ₹12,570.00 |
Key Executives
Whole-Time Director
Mr. Govind Das Garg B.Tech.
Gender: male
Year Born: 1946
FAQs about Parenteral Drugs (India) Limited
Who is the CEO of the company?
The CEO is Govind Das Garg.
What is the current market price of the stock?
The current price is ₹2.90.
What is the 52-week price range?
The range is ₹2.7-2.9.
What is the market capitalization of the company?
The market capitalization is ₹10.11 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -0.11.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Parenteral Drugs (India) Limited (ISIN: ) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹10.11 crores and an average daily volume of 0 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.